Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Drug Manufacturers - Specialty & Generic

Healthcare
$28.96 +1.17%

+$0.51 today

Market cap
$6.02B
Beta
0.54
P/E (TTM)
-87.6
EPS (TTM)
-$0.50
52W Low $30.83High $59.68

Volume 2.71M

Average 0.64M

SUPN Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Supernus Pharmaceuticals, Inc.NASDAQ: SUPN

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue growth accelerates

Q2 FY2026 cost of revenue of $33.67M rose 100.1% year over year, ahead of the +29.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 43.9% from the prior quarter. Over 3 fiscal years it compounded at -5.1% a year.

Context

  • Cost of revenue amounted to 10.4% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +100.1% holds above the trailing-twelve-month pace of +29.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$33.67M+43.9% QoQ
Last fiscal yearDec 2025
$74.56M-4.3% YoY
LTMJun 2026
$99.03M+29.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.1%——
1 year-4.3%——
3-year CAGR-5.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
74.56M USD
Year-over-year change
-4.3%
4-year CAGR
-0.2%

Cost of Revenue vs competitors

How SUPN compares with its peers on the latest reported figures

  • SUPN's LTM Jun 2026 cost of revenue of $99.03M is the lowest of the 3 companies compared; the peer median is $306.64M.
  • Its year-over-year change of +29.8% is the 2nd highest of 3, against a peer median of +26.4%.
  • Cost of revenue amounts to 11.9% of revenue for SUPN, versus a peer median of 28.2%.
SUPN Competitors Peer median
Cost of Revenue for SUPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$313.15M +11.4%+7.6%39.3%
ALKSAlkermes plcLTM Sep 2026$300.12M +41.3%-3.4%17.1%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$99.03M +29.8%-5.1%11.9%
Peer median (excluding SUPN) $306.64M+26.4%+2.1%28.2%

Competitors are the stored peer set for SUPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue579.78M667.24M607.52M661.82M718.95M
Cost of Revenue75.06M87.22M83.78M77.91M74.56M
Gross Profit504.71M580.02M523.74M583.91M644.39M
Gross Margin87.1%86.9%86.2%88.2%89.6%
Research & Development90.47M74.55M91.59M108.8M106.24M
Selling, General & Admin304.76M377.22M336.36M335.78M485.56M
Operating Expenses418.69M533.89M529.01M502.25M681.25M
Depreciation & Amortization32.6M85.54M84.86M80.41M91.56M
EBITDA129.19M153.36M90.04M178.28M42.53M
EBITDA Margin22.3%23.0%14.8%26.9%5.9%
Operating Income86.03M46.12M(5.27M)81.67M(36.86M)
Operating Margin14.8%6.9%-0.9%12.3%-5.1%
Interest Income10.57M21.69M10.45M16.2M13.25M
Interest Expense23.42M7.07M2.42M00
Other Income / Expenses(12.85M)14.62M8.04M16.2M(12.17M)
Income Before Tax73.18M60.74M2.77M97.87M(49.03M)
Pre-Tax Margin12.6%9.1%0.5%14.8%-6.8%
Income Tax Expense19.75M32K1.45M24.01M(10.48M)
Net Income53.42M60.71M1.32M73.87M(38.55M)
Net Margin9.2%9.1%0.2%11.2%-5.4%
EPS (Basic)1.011.130.021.34(0.68)
EPS (Diluted)0.981.040.021.32(0.68)
Weighted Avg Shares53.1M53.67M54.54M55.1M56.45M
Weighted Avg Shares (Diluted)54.36M61.68M55.51M55.96M56.45M

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Intrinsic Alpha fair value

Locked

Current Price

$28.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.